Loading...
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
AIMS: The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for pati...
Na minha lista:
Udgivet i: | Br J Clin Pharmacol |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
John Wiley & Sons, Ltd
2015
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4631173/ https://ncbi.nlm.nih.gov/pubmed/25900065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12662 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|